Moderna

Moderna's capital allocation score of 72/100 suggests a generally sound approach to managing its capital structure and investments, despite the substantial operating losses. This relatively strong score likely reflects a healthy balance sheet with minimal debt, providing flexibility for strategic investments.

The company, having accumulated significant cash during the pandemic, is now deploying this capital into extensive research and development to build out its pipeline, aiming to diversify beyond the COVID-19 vaccine.

However, the TTM Free Cash Flow of $-10.54B indicates that while capital may be allocated towards promising R&D initiatives, these investments are not yet yielding positive returns or offsetting the substantial operational cash burn.

In the biotechnology industry, significant capital outlays for R&D are standard, often leading to negative cash flow for extended periods before potential blockbuster drugs emerge.

The challenge for Moderna's management is to ensure these substantial investments lead to commercially viable products that reverse the current trend of severe unprofitability and generate sustainable shareholder value.